Skip to main content
Erschienen in: Familial Cancer 4/2010

01.12.2010

Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population

verfasst von: Lucian Negura, Nancy Uhrhammer, Anca Negura, Vlad Artenie, Eugen Carasevici, Yves-Jean Bignon

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Breast cancer is the most common cancer in women worldwide, including Romania, where its incidence has increased significantly during the last decade. Ovarian cancer is the fourth leading cause of mortality by cancer in women. BRCA1 and BRCA2 are major cancer predisposition genes, responsible for a large percentage of hereditary breast and ovarian cancer (HBOC) families. We investigated 17 patients from unrelated HBOC families in north-eastern Romania, screening for mutations in BRCA1 and BRCA2 by mutation-specific PCR and by dideoxy sequencing. We identified four BRCA1 and two BRCA2 mutations in the 17 families. The overall mutation frequency was 41% (7/17; 5 BRCA1 and 2 BRCA2). Two mutations (BRCA1 c.2241dupC and BRCA2 c.8680C>T) were novel and not listed in the BIC database. Two recurrent BRCA1 mutations (c.5266dupC and c.181T>G), previously described among Ashkenazi Jewish and Eastern European populations, were also found. Two unclassified variants (UV) were found, one of which was novel (BRCA2 c.4589A>G). Medical follow-up for mutation carriers was implemented. Our study is the first molecular investigation of the role of the BRCA genes in breast and ovarian cancer in Romania.
Literatur
2.
Zurück zum Zitat King MC, Marks JH, Mandell JB, for The New York BreastCancer Study Group (2003) Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed King MC, Marks JH, Mandell JB, for The New York BreastCancer Study Group (2003) Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2. Science 302:643–646CrossRefPubMed
5.
Zurück zum Zitat Sun CC, Ramirez PT, Bodurka DC (2007) Quality of Life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18–29CrossRefPubMed Sun CC, Ramirez PT, Bodurka DC (2007) Quality of Life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18–29CrossRefPubMed
6.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMed
7.
Zurück zum Zitat Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265(5181):2088–2090CrossRefPubMed Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D et al (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science 265(5181):2088–2090CrossRefPubMed
8.
Zurück zum Zitat Narod SA (2002) Modifiers of risk of hereditary breast and ovarian cancer. Nature Rev Cancer 2(2):113–123CrossRef Narod SA (2002) Modifiers of risk of hereditary breast and ovarian cancer. Nature Rev Cancer 2(2):113–123CrossRef
9.
Zurück zum Zitat Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PDP, Whittemore A, Haile RW (2004) Breast cancer risks for BRCA1/2 carriers. Science 306:2187–2188CrossRefPubMed Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PDP, Whittemore A, Haile RW (2004) Breast cancer risks for BRCA1/2 carriers. Science 306:2187–2188CrossRefPubMed
10.
Zurück zum Zitat Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 mutations and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMed Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 mutations and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457–1462PubMed
11.
Zurück zum Zitat Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMed Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMed
12.
Zurück zum Zitat Bermejo JL, Hemminiki K (2006) Risks of cancer and families. J Natl Cancer Inst 98(8):563–564CrossRefPubMed Bermejo JL, Hemminiki K (2006) Risks of cancer and families. J Natl Cancer Inst 98(8):563–564CrossRefPubMed
13.
Zurück zum Zitat Chetrit A et al (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26(1):9–10CrossRef Chetrit A et al (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26(1):9–10CrossRef
14.
Zurück zum Zitat Uhrhammer N, Bornes S, Bignon Y-J (2005) Quelle place tiennent les gènes BRCA1 et BRCA2 dans les risques héréditaires de cancer de l’ovaire? Oncologie 7:526–530CrossRef Uhrhammer N, Bornes S, Bignon Y-J (2005) Quelle place tiennent les gènes BRCA1 et BRCA2 dans les risques héréditaires de cancer de l’ovaire? Oncologie 7:526–530CrossRef
15.
Zurück zum Zitat Honrado E, Benitez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18(10):1305–1320CrossRefPubMed Honrado E, Benitez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18(10):1305–1320CrossRefPubMed
17.
Zurück zum Zitat Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388CrossRefPubMed Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388CrossRefPubMed
18.
Zurück zum Zitat Chan P, Wong B, Ozcelik H, Cole D (1999) Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR. Clin Chem 45(8):1285–1287PubMed Chan P, Wong B, Ozcelik H, Cole D (1999) Simple and rapid detection of BRCA1 and BRCA2 mutations by multiplex mutagenically separated PCR. Clin Chem 45(8):1285–1287PubMed
20.
Zurück zum Zitat Gorski B et al (2000) Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. Am J Hum Genet 66:1963–1968CrossRefPubMed Gorski B et al (2000) Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer. Am J Hum Genet 66:1963–1968CrossRefPubMed
21.
Zurück zum Zitat Grzybowska E et al (2002) Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol 49(2):351–356PubMed Grzybowska E et al (2002) Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim Pol 49(2):351–356PubMed
22.
Zurück zum Zitat Janiszewska H et al (2003) Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujavy region of Poland. Clin Genet 64:502–508CrossRefPubMed Janiszewska H et al (2003) Frequency of three BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania-Kujavy region of Poland. Clin Genet 64:502–508CrossRefPubMed
23.
Zurück zum Zitat Bar-Sade RB et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazi. Hum Mol Gen 7(5):801–805CrossRefPubMed Bar-Sade RB et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazi. Hum Mol Gen 7(5):801–805CrossRefPubMed
24.
Zurück zum Zitat Fitzgerald MG et al (1996) Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334(3):143–149CrossRefPubMed Fitzgerald MG et al (1996) Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334(3):143–149CrossRefPubMed
25.
Zurück zum Zitat Ciernikova S et al (2006) Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2):97–102PubMed Ciernikova S et al (2006) Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2):97–102PubMed
26.
Zurück zum Zitat Jasinska A et al (2000) Prevalence of BRCA1 founder mutations in Western Poland. Hum Mutat 389:1–7 Jasinska A et al (2000) Prevalence of BRCA1 founder mutations in Western Poland. Hum Mutat 389:1–7
27.
Zurück zum Zitat Ozsurek O et al (2001) Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clin Genet 60:470–471CrossRef Ozsurek O et al (2001) Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clin Genet 60:470–471CrossRef
28.
Zurück zum Zitat Loginova AN et al (2003) Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families. Bull Exp Biol Med 136(3):276–278CrossRefPubMed Loginova AN et al (2003) Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families. Bull Exp Biol Med 136(3):276–278CrossRefPubMed
29.
Zurück zum Zitat Van der Looij M et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86(5):737–740CrossRefPubMed Van der Looij M et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86(5):737–740CrossRefPubMed
30.
Zurück zum Zitat Kataki A et al (2005) Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals—correlation with clinicopathological data. Clin Genet 67:322–329CrossRefPubMed Kataki A et al (2005) Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals—correlation with clinicopathological data. Clin Genet 67:322–329CrossRefPubMed
31.
Zurück zum Zitat Yazici H et al (2000) BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 83(6):737–742CrossRefPubMed Yazici H et al (2000) BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 83(6):737–742CrossRefPubMed
32.
Zurück zum Zitat Eisinger F et al (2004) Identification and management of hereditary predisposition to cancer of the breast and the ovary. Bull Cancer 91(3):219–237PubMed Eisinger F et al (2004) Identification and management of hereditary predisposition to cancer of the breast and the ovary. Bull Cancer 91(3):219–237PubMed
Metadaten
Titel
Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population
verfasst von
Lucian Negura
Nancy Uhrhammer
Anca Negura
Vlad Artenie
Eugen Carasevici
Yves-Jean Bignon
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9361-6

Weitere Artikel der Ausgabe 4/2010

Familial Cancer 4/2010 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.